Argan INC Form 4 insider transactions

ARGAN Inc. Director Peter W. Getsinger reported selling common stock totaling 10,595 shares after exercising stock options.

ARGAN Inc. Director William F. Leimkuhler exercised multiple stock options on January 7, 2026, increasing his direct beneficial ownership of common stock.

ARGAN Director William F. Leimkuhler reported the sale of 200 shares of common stock by two trusts and a gift of 500 shares.

ARGAN Director Peter W. Getsinger reported a bona fide gift of 750 shares of the company's common stock on December 23, 2025, reducing his direct beneficial ownership to 11,847 shares.

ARGAN Inc. Director John R. Jeffrey Jr. acquired common stock through the vesting of restricted stock units on December 14 and 16, 2025.

Argan Inc. Director James W. Quinn increased his direct beneficial ownership of common stock through the routine vesting of restricted stock units on December 14 and 16, 2025.

ARGAN Director Peter W. Getsinger increased his direct beneficial ownership of common stock through the vesting of restricted stock units.

ARGAN Director Cynthia Flanders increased her direct beneficial ownership of common stock by 2,700 shares through the vesting of time-based restricted stock units.

Argan Inc. Director William F. Leimkuhler reported the vesting of time-based restricted stock units, resulting in the acquisition of 2,700 common shares.

Argan Inc. Director James W. Quinn reported gifting 1,000 shares to a donor-advised fund, which subsequently sold them for $328.04 per share.

Argan Inc. Director William F. Griffin Jr. transferred 140,976 shares of common stock between two trusts, a revocable trust and a GRAT trust, on December 5, 2025.

ARGAN Inc. Director William F. Griffin Jr. reported an internal transfer of 5,000 common shares between two family trusts, resulting in no change to his overall beneficial ownership.

Argan Inc. Director Peter W. Getsinger sold a total of 8,493 shares of common stock for approximately $2.5 million in open market transactions in October 2025.

ARGAN Director Peter W. Getsinger exercised stock options and subsequently gifted and transferred a portion of his common stock holdings.

Argan Inc.'s CEO of Gemma, Charles Edwin Collins IV, exercised stock options and subsequently sold 10,000 common shares for proceeds exceeding $3 million.

ARGAN's CEO, Charles Edwin Collins IV, exercised stock options and subsequently sold a portion of his common stock holdings.

ARGAN Director James W. Quinn reported a transfer of 5,578 common shares from his GRAT to direct ownership, a change in beneficial ownership form.

ARGAN Inc.'s President and CEO, David Hibbert Watson, reported open market sales of common stock and a gift to a donor-advised fund.

ARGAN Inc. Director Cynthia Flanders sold 15,000 shares of common stock on October 8, 2025, at an average price of $271.96 per share, reducing her direct beneficial ownership to 16,428 shares.

ARGAN Inc.'s CEO, Charles Edwin Collins IV, exercised stock options and simultaneously sold 5,000 common shares for a significant profit.

ARGAN Inc. Director James W. Quinn sold 13,444 shares of common stock for approximately $3.6 million, executed under a Rule 10b5-1 plan.

ARGAN Inc. Director William F. Leimkuhler sold 11,806 shares of common stock for approximately $3.2 million on October 1, 2025, under a Rule 10b5-1 plan.

ARGAN Inc. Director John R. Jeffrey Jr. reported the sale of 4,698 shares of common stock for approximately $1.26 million.

Argan Inc.'s CEO of Gemma, Charles Edwin Collins IV, exercised stock options and simultaneously sold an equal number of common shares, realizing a significant profit.

ARGAN Inc. Director Peter W. Getsinger sold 1,000 shares of common stock for $264.54 per share on September 19, 2025, under a pre-arranged 10b5-1 plan.

ARGAN Director Karen Sweeney reported the sale of 390 shares of common stock at $264.25 per share, reducing her direct beneficial ownership to 1,315 shares.

ARGAN Director James W. Quinn reported the sale of 16,557 shares of common stock in two separate transactions, executed under a Rule 10b5-1 plan.

Argan Inc.'s CEO, Charles Edwin Collins IV, exercised stock options and simultaneously sold 7,500 shares of common stock, realizing a significant gain.

ARGAN Director Peter W. Getsinger exercised stock options and subsequently sold a portion of his common stock holdings.

Rainer H. Bosselmann, former CEO and Director of Argan Inc., filed his final SEC Form 4, indicating he is no longer subject to Section 16 reporting requirements.